[{"from": "human", "value": "Provide a description of this molecule. [C][N][Branch2][Ring1][Branch2][C][C][=C][N][=C][C][=Branch1][Ring2][=N][Ring1][=Branch1][C][=Branch1][=Branch2][=N][C][=Branch1][Ring2][=N][Ring1][#Branch1][N][N][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=Branch1][C][=O][N][C@@H1][Branch1][Branch2][C][C][C][=Branch1][C][=O][O][C][=Branch1][C][=O][O]"}, {"from": "gpt", "value": "The molecule is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.  Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments.  Methotrexate was granted FDA approval on 7 December 1953."}]